Navigation Links
Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study
Date:10/12/2010

By Jenifer Goodwin
HealthDay Reporter

TUESDAY, Oct. 12 (HealthDay News) -- Patients having heart surgery who receive fewer blood transfusions do just as well as those who receive more, new research finds, and yet the rate of blood transfusions varies widely among U.S. hospitals.

The studies are published in the Oct. 13 issue of the Journal of the American Medical Association.

In the first study, researchers in Brazil divided 502 cardiac surgery patients into two groups: one received blood transfusions when the hemoglobin concentrations in their blood fell to 30 percent. The other group received blood transfusions when their hemoglobin levels dropped to 24 percent.

Patients who received transfusions at the lower hemoglobin concentration fared just as well in the 30 days after surgery as those who received transfusions at the higher hemoglobin level.

Only 47 percent of patients whose surgeons waited until their blood hemoglobin levels had fallen to 24 percent were given transfusions compared to 78 percent of those in the 30 percent hemoglobin concentration group.

Why should this matter to patients?

Hemoglobin concentration is the percentage of the blood made up of red blood cells. A normal hemoglobin level is about 42 percent, explained Dr. Timothy Gardner, an American Heart Association spokesman and a cardiac surgeon at Christiana Care Health System in Wilmington, Del. Gardner was not involved in the research.

Hemoglobin levels that drop too far can cause severe anemia, which causes the blood to lose too much of its oxygen-carrying capacity and raises the risk of death and other complications.

Yet blood transfusion itself carries risks, Gardner said. Prior research has found an association between transfusions and greater risk of death and problems including renal failure and infection.

"What this study shows is that in patients that don't have a lot of other problems, you don't need to transfuse them to higher levels," Gardner said. "They will do just as well with a lower level of red blood cell concentration during the operative and early postoperative periods."

After blood loss during heart surgery, hemoglobin concentrations usually rebound in about a month or two, Gardner explained.

Yet around the nation, the rate of transfusions during cardiac surgery varies widely, according to a second study in the same journal by researchers from Duke University in Durham, N.C.

Researchers analyzed data on more than 100,000 patients from nearly 800 U.S. hospitals who were getting coronary artery bypass graft surgery for the first time. They found some hospitals transfused almost no one, while other hospitals transfused nearly everyone.

The percentage of patients given red blood cells ranged from 7.8 percent to 92.8 percent; for fresh-frozen plasma, the range was 0 to 97.5 percent, while platelets ranged from 0.4 percent to 90.4 percent, according to the report.

The researchers found no association between post-surgery patient deaths and the hospital's rate of transfusions.

Patients in academic hospitals, hospitals that performed few coronary artery bypass graft operations and hospitals in Texas, Louisiana, Arkansas and Oklahoma were more likely to get transfusions than those in other hospitals, though taken together, those differences accounted for only 11 percent of the variation, the study authors noted.

Patient characteristics, including age and other health conditions, accounted for another 20 percent, they found.

Differences in surgical techniques that lead to more or less bleeding or a culture of transfusing patients routinely may help explain some of the variation, according to the report.

Dr. Lawrence Goodnough, a professor of pathology and medicine at Stanford University who co-authored an accompanying editorial, said the findings suggest that transfusion rates should be one factor taken into account when rating hospital performance.

"Blood transfusions should be a quality indicator that can help track how carefully surgical patients are being handled," Goodnough said.

Taken together, the studies suggest hospitals may need to rethink their transfusion practices, Gardner said, noting that in some patients transfusing to the higher hemoglobin level is appropriate.

"The combination of the two articles is forcing heart surgeons to reconsider their transfusion practices during heart surgery," Gardner said. "The Brazilian study suggests we can safely treat many patients without transfusion. The other study shows that as a community of heart surgeons, there is still a lot of variation in practices. It's a double whammy."

More information

The U.S. National Heart, Lung, and Blood Institute has more on blood transfusions.

SOURCES: Timothy J. Gardner, M.D., American Heart Association spokesman, and medical director, Center for Heart & Vascular Health, Christiana Care Health System in Wilmington, Del.; Lawrence Goodnough, M.D., professor, pathology and medicine, and director, transfusion service, Stanford Medical Center, Palo Alto, Calif.; Oct. 13, 2010, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Medical researchers break down costs to care for heart failure patients at the end of life
2. End-of-life care patterns shift for patients with heart failure in both US and Canada
3. Certain new therapies for age-related eye disease do not appear to increase heart risks
4. No Heart Benefit Seen From Folic Acid Supplements
5. Heartburn Drugs, Plavix Seem Safe to Take Together
6. Once-Promising Heart Failure Drug Fails in Trial
7. Workplace Noise Tied to Heart Disease Risk
8. Testosterone Could Boost Health of Heart Failure Patients
9. Dental Care Linked to Heart Health in Older Women
10. Heart, kidney, diabetes and cancer MEP groups league against chronic disease to seek European commitment
11. Women who get dental care have lower risk of heart disease, says study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study
(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... , ... “Reflections of God’s Work”: an enlightening collection of life lessons leading ... of published author, Jerri Broglin, a survivor of great loss who gained insight on ... eye-opener for those searching for answers, as we are finding the answers that are ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology: